Business Context and Reporting Period
Company: Atyr Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2022
Event: Entry into a Material Definitive Agreement (Lease)
Key Financial Metrics
This filing reports on a specific contractual agreement rather than periodic financial performance. Consequently, revenue, profit, cash flow, margins, debt, and liquidity metrics are not disclosed in this document.
Lease Financial Terms:
- Base Rent: $5.75 per square foot per month for the first 12 months, subject to approximately 3.0% annual upward adjustments.
- Tenant Improvement Allowance: $5,450,080.00 (with an option for an additional $592,400.00).
- Security Deposit: $732,680.00 (provided via letter of credit).
- Additional Rent: If the additional allowance is utilized, it will be repaid as additional monthly base rent amortized at 8.0% per annum.
Material Changes
The Company entered into a new lease agreement for approximately 23,696 rentable square feet of office and laboratory space located at 10240 Sorrento Valley Road, San Diego, California. This represents a material commitment to future operating expenses and capital deployment for facility improvements.
Outlook, Risks, and Contingencies
Lease Term and Commencement: The lease term is 124 months, commencing on the earlier of April 1, 2023, or the completion of leasehold improvements (but not sooner than March 1, 2023).
Extension Option: The Company holds one option to extend the lease term for five years at fair market rent.
Cost Obligations: In addition to base rent, the Company is responsible for its proportional share of building operating and tax expenses, as well as separately metered utilities and janitorial costs.
Investor Verification Checklist
- Verify the total projected cost of the lease over the 124-month term, including the 3.0% annual rent escalations.
- Confirm the Company's current cash position to ensure it can fund the $732,680.00 letter of credit and any upfront costs prior to the lease commencement.
- Assess the impact of the potential additional $592,400.00 tenant improvement allowance on future monthly cash outflows due to the 8.0% amortization.
- Review the full text of the Lease agreement (Exhibit 10.1) for specific definitions of "operating and tax expenses" to understand variable cost exposure.